Early start and stop of biologics: Has the time come?

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Van Vollenhoven, Ronald F ^a   Nagy, György ^b   Tak, Paul P ^c,d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Biologics; Rheumatoid arthritis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB;

COST; DISEASE ACTIVITY; DRUG THERAPY; HUMAN; NOTE; REMISSION; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; HUMANS; RHEUMATIC FEVER; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893505901     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-25     Document Type: Note

References (26)

1. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
2. Tak PP. Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis?. Best Pract Res Clin Rheumatol 2001, 15:17-26.
3. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995, 34:74-78.
4. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784. 10.1002/art.23721, 18512708.
5. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443. 10.1002/art.20568, 15529377.
6. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37. 10.1002/art.21519, 16385520.
7. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681. 10.1016/S0140-6736(04)15640-7, 15001324.
8. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009, 374:459-466. 10.1016/S0140-6736(09)60944-2, 19665644.
9. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012, 379:1712-1720. 10.1016/S0140-6736(12)60027-0, 22464340.
10. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012, 64:2824-2835. 10.1002/art.34498, 22508468.
11. Rantalaiho V, Kautiainen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis 2013, [Epub ahead of print].
12. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353:1568-1573. 10.1016/S0140-6736(98)08513-4, 10334255.
13. Horslev-Petersen K, Hetland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2013, [Epub ahead of print].
14. de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013, 72:72-78. 10.1136/annrheumdis-2011-201162, 22679301.
15. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013, 369:307-318. 10.1056/NEJMoa1303006, 23755969.
16. Eriksson JK, Neovius M, Bratt J, et al. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. JAMA Intern Med 2013, 173:1407-1414. 10.1001/jamainternmed.2013.7801, 23817631.
17. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269. 10.1016/S0140-6736(04)16676-2, 15262104.
18. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449. 10.1136/ard.2007.071092, 2111604, 17519278.
19. Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012, 71:989-992. 10.1136/annrheumdis-2011-201066, 22402142.
20. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96. 10.1136/ard.2008.105197, 3747519, 19297346.
21. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009, 68:1870-1877. 10.1136/ard.2008.101121, 2770104, 19124524.
22. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rhuem Dis 2011, 70:39-46.
23. Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012, 71:1921-1923. 10.1136/annrheumdis-2012-201893, 22941769.
24. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27-35. 10.1002/art.20712, 15641102.
25. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007, 56:2129-2134. 10.1002/art.22718, 17599726.
26. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2013, [Epub ahead of print].